| Literature DB >> 36093206 |
João Victor Silva-Silva1,2, Rosiane Fernandes Moreira3, Luciano Almeida Watanabe3, Celeste da Silva Freitas de Souza1, Daiana de Jesus Hardoim1, Noemi Nosomi Taniwaki4, Alvaro Luiz Bertho5,6, Kerolain Faoro Teixeira7, Arthur Ribeiro Cenci7, Thiago Henrique Doring7, José Wilmo da Cruz Júnior7, Aldo Sena de Oliveira7, Patrícia Santana Barbosa Marinho3, Kátia da Silva Calabrese1, Andrey Moacir do Rosario Marinho3, Fernando Almeida-Souza1,8.
Abstract
Leishmaniasis represents a serious world health problem, with 1 billion people being exposed to infection and a broad spectrum of clinical manifestations with a potentially fatal outcome. Based on the limitations observed in the treatment of leishmaniasis, such as high cost, significant adverse effects, and the potential for drug resistance, the aim of the present study was to evaluate the leishmanicidal activity of the compounds pseurotin A and monomethylsulochrin isolated from the biomass extract of Aspergillus sp. The chromatographic profiles of the extract were determined by high-performance liquid chromatography coupled with a diode-array UV-Vis detector (HPLC-DAD-UV), and the molecular identification of the pseurotin A and monomethylsulochrin were carried out by electrospray ionization mass spectrometry in tandem (LC-ESI-MS-MS) and nuclear magnetic resonance (NMR). Antileishmanial activity was assayed against promastigote and intracellular amastigote of Leishmania amazonensis. As a control, cytotoxicity assays were performed in non-infected BALB/c peritoneal macrophages. Ultrastructural alterations in parasites were evaluated by transmission electron microscopy. Changes in mitochondrial membrane potential were determined by flow cytometry. Only monomethylsulochrin inhibited the promastigote growth (IC50 18.04 ± 1.11 µM), with cytotoxicity to peritoneal macrophages (CC50 5.09 91.63 ± 1.28 µM). Activity against intracellular amastigote forms (IC50 5.09 ± 1.06 µM) revealed an increase in antileishmanial activity when compared with promastigotes. In addition to a statistically significant reduction in the evaluated infection parameters, monomethylsulochrin altered the ultrastructure of the promastigote forms with atypical vacuoles, electron-dense corpuscles in the cytoplasm, changes at the mitochondria outer membrane and abnormal disposition around the kinetoplast. It was showed that monomethylsulochrin leads to a decrease in the mitochondrial membrane potential (25.9%, p = 0.0286). Molecular modeling studies revealed that monomethylsulochrin can act as inhibitor of sterol 14-alpha-demethylase (CYP51), a therapeutic target for human trypanosomiasis and leishmaniasis. Assessed for its drug likeness, monomethylsulochrin follows the Lipinski Rule of five and Ghose, Veber, Egan, and Muegge criteria. Furthermore, monomethylsulochrin can be used as a reference in the development of novel and therapeutically useful antileishmanial agents.Entities:
Keywords: ADMET; CYP51; Leishmania amazonensis; electron microscopy; flow cytometry; mitochondrial membrane potential; monomethylsulochrin
Mesh:
Substances:
Year: 2022 PMID: 36093206 PMCID: PMC9452909 DOI: 10.3389/fcimb.2022.974910
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Figure 1Chromatogram of F2 fraction of ethyl acetate extract obtained from Aspergillus sp. biomass. HPLC-DAD in preparative mode using a chromatograph Waters 1525 Binary HPLC Pump equipped with Waters 2998 DAD and Sunfire™ prep C18 OBD column (5 µm, 19 mm × 150 mm), 500 μl of injected volume, gradient elution H2O/MeOH (50–100%) for 30 min, flow of 13.0 ml/min. The wavelength scanning was in the range of 210–600 nm. Pseurotin A (1) and monomethylsulochrin (2).
Figure 2Chemical structure of compounds isolated from Aspergillus sp. (1) pseurotin A and (2) monomethylsulochrin.
Antileishmanial activity, cytotoxicity in BALB/c peritoneal macrophages, and selectivity index after 24 h of treatment with compounds from Aspergillus sp. and amphotericin B.
| Compounds | Cytotoxicity |
| |||
|---|---|---|---|---|---|
| CC50 (µM) | Promastigote | Intracellular amastigote | |||
| IC50 (µM) | SIpro | IC50 (µM) | SIama | ||
| Pseurotin A | 654.38 ± 1.19 | > 500 | ND | ND | ND |
| Monomethylsulochrin | 91.63 ± 1.28 | 18.04 ± 1.11 | 5.08 | 5.09 ± 1.06 | 18.00 |
| Amphotericin B | 8.45 ± 1.08 | 0.027 ± 1.14 | 312.96 | 0.629 ± 1.39 | 13.43 |
Data represents mean ± SD of at least two experiments done in triplicate; CC50: cytotoxic concentration for 50% of peritoneal macrophage; IC50: inhibitory concentration for 50% of parasites; SIpro (selectivity index) = CC50 macrophages/IC50 promastigote forms. SIama (selectivity index) = CC50 macrophages/IC50 amastigote forms; ND: not determined.
Figure 3In vitro effects of monomethylsulochrin and amphotericin B against Leishmania amazonensis after 24 h of treatment. Light microscopy 24 h after amphotericin B or monomethylsulochrin treatment at 0.75 or 6 μM, respectively (A). Infection parameters of BALB/c peritoneal macrophages infected with L. amazonensis and treated with monomethylsulochrin (B–D) or amphotericin B (E–G). Intracellular amastigotes inside macrophages (arrows). Data represent mean ± SD of two independent experiments realized in triplicate. *p < 0.05, **p < 0.01, and ***p < 0.001 when compared with the untreated group by the Mann–Whitney test.
Figure 4Ultrastructural analysis of Leishmania amazonensis promastigote forms. (A) Untreated parasites. (B–E) Parasites treated with monomethylsulochrin (18.04 μM) for 24 h. (F) Statistical differences data in the quantification of the vacuoles, lipid corpuscles, and mitochondria damage between the cells in the untreated group and the groups treated with monomethylsulochrin are shown. Images show several vacuoles dispersed in the cytoplasm (black asterisks), lipid corpuscles (white asterisks), vesicles with electron-dense material inside (arrows), and changes at the mitochondria outer membrane and abnormal disposition around the kinetoplast. f: flagellum; k: kinetoplast; n: nucleus; LC: lipid corpuscles. Images are representative of two independent experiments from five untreated and at least 10 treated cells. Data are presented as mean ± SD, and the difference between treated and untreated group was evaluated by Mann–Whitney test with *p > 0.05 and **p > 0.01.
Figure 5Flow cytometry of promastigote forms of Leishmania amazonensis mitochondrial membrane potential (ΔΨm) treated with monomethylsulochrin. (A) FSC versus SSC dot plot to define L. amazonensis-promastigotes population. (B) TMRE-staining histogram of control samples (unstained and untreated parasites), gated on “promastigotes.” (C) TMRE-staining histogram of monomethylsulochrin-untreated parasites. (D) L. amazonensis promastigotes killed by heat (60°C). (E) Representative histogram of L. amazonensis promastigotes treated with 18.04 μM of monomethylsulochrin. (F) Statistically significant differences were observed between the percentages of cells marked with TMRE in the untreated group and the groups treated with monomethylsulochrin, at the IC50 concentration (18.04 μM). *p < 0.05, when compared with the untreated group by Mann–Whitney test. Images are representative of two independent experiments carried out at least in triplicate.
Figure 6Redocking of the co-crystallized ligand HEM on the active site of CYP51 (PDB ID 3TIK). In green, the best pose of the co-crystallized ligand generated by the ChemPLP function and, in yellow, its crystallographic conformation.
Figure 72D diagram of the interaction of monomethylsulochrine at the active site of CYP51 (PDB ID 3TIK). Hydrogen bonds are shown as arrows in purple, hydrophobic interactions in green lines, and polar interactions in light blue lines.
Figure 8Monomethylsulochrine (carbon represented as orange sticks) in the active site of CYP51 (PDB ID 3TIK). Hydrogen bonds are shown as dashed lines.
Predicted physicochemical, drug-likeness, and medicinal chemistry properties for monomethylsulochrin compound and amphotericin B.
| Property/Model Name | Compounds | |
|---|---|---|
| Monomethylsulochrin | Amphotericin B | |
|
| ||
| Molecular Weight | 346.335 | 924.091 |
| # Rotatable bonds | 6 | 3 |
| # H-bond acceptors | 7 | 18 |
| # H-bond donors | 2 | 12 |
| Surface Area | 143.930 | 380.536 |
| TPSA (Å2) | 102.29 | 319.61 |
| Lipophilicity (Log Po/w) | 2.71 | 3.76 |
|
| ||
| Lipinski | Yes; 0 violation | No; 3 violations: MW>500, NorO>10, NHorOH>5 |
| Ghose | Yes | No; 3 violations: MW>480, MR>130, #atoms>70 |
| Veber | Yes | No; 1 violation: TPSA>140 |
| Egan | Yes | No; 1 violation: TPSA>131.6 |
| Muegge | Yes | No; 4 violations: MW>600, TPSA>150, H-acc>10, H-don>5 |
|
| ||
| PAINS | 0 alert | 0 alert |
| Brenk | 0 alert | 0 alert |
| Lead-likeness | Yes | No; 1 violation: MW>350 |
| Synthetic accessibility | 2.98 | 10.00 |
#, number; TPSA, topological polar surface area; PAINS, pan-assay interference compounds; MW, molecular weight.
In silico pharmacokinetics and toxicity properties of monomethylsulochrin compound and amphotericin B.
| Property | Model Name | Compounds | |
|---|---|---|---|
| Monomethylsulochrin | Amphotericin B | ||
| Absorption | Water solubility (log mol/L) | -4.129 | -2.937 |
| Caco-2 permeability (log Papp in 10−6 cm/s) | 1.136 | -0.597 | |
| Intestinal absorption – human (% Absorbed) | 76.803 | 0 | |
| Skin Permeability (log Kp) | -2.761 | -2.735 | |
| P-glycoprotein substrate | Yes | Yes | |
| P-glycoprotein I inhibitor | Yes | No | |
| P-glycoprotein II inhibitor | No | No | |
| Distribution | Human ssVD (log L/kg) | -0.344 | -0.37 |
| BBB permeability (log BB) | -0.416 | -2.058 | |
| CNS permeability (log PS) | -3.138 | -3.718 | |
| Metabolism | CYP2D6 substrate | No | No |
| CYP3A4 substrate | No | No | |
| CYP1A2 inhibitor | No | No | |
| CYP2C19 inhibitor | No | No | |
| CYP2C9 inhibitor | No | No | |
| CYP2D6 inhibitor | No | No | |
| CYP3A4 inhibitor | No | No | |
| Excretion | Total Clearance (log ml/min/kg) | 0.724 | -1.495 |
| Renal OCT2 substrate | No | No | |
| Toxicity | AMES toxicity | No | No |
| Human max. tolerated dose (log mg/kg per day) | 0.843 | 0.292 | |
| hERG I inhibitor | No | No | |
| hERG II inhibitor | No | No | |
| Oral Rat Acute Toxicity LD50 (mol/kg) | 2.024 | 2.518 | |
| Oral Rat Chronic Toxicity LOAEL (log mg/kg bw per day) | 2.318 | 2.049 | |
| Hepatotoxicity | No | No | |
| Skin Sensitization | No | No | |
|
| 0.34 | 0.285 | |
| Minnow toxicity (log mM) | 2.052 | 11.261 | |
VDss, steady state volume of distribution; BBB, brain–blood barrier; CNS, central nervous system; OCT2, organic cation transporter 2; AMES, Salmonella/microsome mutagenicity assay; hERG, human ether-a-go-go gene; LOAEL, lowest dose of a compound that resulted in an observed adverse effect.